Skip to main content
Journal cover image

Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Subvariant Neutralization Following a Primary Vaccine Series of NVX-CoV2373 and BNT162b2 Monovalent Booster Vaccine.

Publication ,  Journal Article
Babu, TM; Shen, X; McClelland, RS; Wang, Z; Selke, S; Wilkens, C; Hauge, KA; McClurkan, CL; Goecker, E; Laing, KJ; Koelle, DM; Greninger, AL ...
Published in: Open Forum Infect Dis
February 2024

We evaluated the immunologic response to a novel vaccine regimen that included 2 doses of NVX-CoV2373 (Novavax) followed by 1 dose of BNT162b2 (Pfizer-BioNTech) monovalent booster vaccine. A durable neutralizing antibody response to Omicron BA.4/BA.5 and BA.1 variants was observed at month 6 after the booster, while immune escape was noted for the XBB.1.5 variant.

Duke Scholars

Published In

Open Forum Infect Dis

DOI

ISSN

2328-8957

Publication Date

February 2024

Volume

11

Issue

2

Start / End Page

ofad673

Location

United States

Related Subject Headings

  • 3207 Medical microbiology
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Babu, T. M., Shen, X., McClelland, R. S., Wang, Z., Selke, S., Wilkens, C., … Wald, A. (2024). Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Subvariant Neutralization Following a Primary Vaccine Series of NVX-CoV2373 and BNT162b2 Monovalent Booster Vaccine. Open Forum Infect Dis, 11(2), ofad673. https://doi.org/10.1093/ofid/ofad673
Babu, Tara M., Xiaoying Shen, R Scott McClelland, Zijun Wang, Stacy Selke, Chloe Wilkens, Kirsten A. Hauge, et al. “Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Subvariant Neutralization Following a Primary Vaccine Series of NVX-CoV2373 and BNT162b2 Monovalent Booster Vaccine.Open Forum Infect Dis 11, no. 2 (February 2024): ofad673. https://doi.org/10.1093/ofid/ofad673.
Babu, Tara M., et al. “Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Subvariant Neutralization Following a Primary Vaccine Series of NVX-CoV2373 and BNT162b2 Monovalent Booster Vaccine.Open Forum Infect Dis, vol. 11, no. 2, Feb. 2024, p. ofad673. Pubmed, doi:10.1093/ofid/ofad673.
Babu TM, Shen X, McClelland RS, Wang Z, Selke S, Wilkens C, Hauge KA, McClurkan CL, Goecker E, Laing KJ, Koelle DM, Greninger AL, Nussenzweig MC, Montefiori DC, Corey L, Wald A. Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Subvariant Neutralization Following a Primary Vaccine Series of NVX-CoV2373 and BNT162b2 Monovalent Booster Vaccine. Open Forum Infect Dis. 2024 Feb;11(2):ofad673.
Journal cover image

Published In

Open Forum Infect Dis

DOI

ISSN

2328-8957

Publication Date

February 2024

Volume

11

Issue

2

Start / End Page

ofad673

Location

United States

Related Subject Headings

  • 3207 Medical microbiology
  • 3202 Clinical sciences